跳至主要内容
临床试验/EUCTR2012-004088-38-SE
EUCTR2012-004088-38-SE进行中(未招募)不适用

Pilot study to downregulate allergic responses in adults with allergic rhinoconjunctivitis by using three intralymphatic injections of grass or birch allergen one month in between during the non-seasonal period. - Pilot-ILIT (Pilot trial to down regulate allergy by IntraLymphatic allergen ImmunoTherapy

Allergy Centre, University Hospital0 个研究点开始时间: 2012年10月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Age 18-50 years,
  • Seasonal allergic symptoms for grass or birch verified by skin prick test.
  • Accepted and signed informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 10
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • The presence of any of the following will exclude the potential study
  • patient from entry into the study:
  • Pregnancy or nursing, or planning for that. Women with childbearing
  • potential should use contraceptives. Condom only is not enough as
  • contraceptive.
  • Autoimmune or collagen disease
  • Grave cardiovascular disease, milder cases decided by the investigator
  • Perennial pulmonary disease, FEV1 < 80 % of predicted, or use of more
  • then 400 microgram budesonide (or equivalent/day)
  • Recent or on-going hepatic disease
  • Recent or on-going renal disease
  • Cancer – as decided by the investigator
  • Any medication with a possible side effect of interfering with the
  • immune response, Previous immuno- or chemotherapy
  • Upper airway disease (non-allergic sinusitis, nasal polyps)
  • Chronic obstructive and restrictive lung disease
  • Disease or conditions rendering the treatment of anaphylactic reactions
  • difficult (symptomatic coronary heart diseases, severe arterial
  • hypertension and treatment with Beta-blockers)
  • Major metabolic disease
  • Known or suspected allergy for addatives in the study product
  • Alcohol or drug abuse
  • Mental incapability of coping with the study
  • Participation in another clinical study within 30 days that could jeopardize this study

研究者

发起方
Allergy Centre, University Hospital

相似试验